Your session is about to expire
← Back to Search
Transdermal System
HP-1050 Patch for Cumulative Irritation and Sensitization Syndrome
Phase 1
Waitlist Available
Research Sponsored by Noven Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours
Awards & highlights
Summary
This trial is testing a new skin patch called HP-1050 to see if it causes any skin irritation or allergic reactions. The study involves healthy women.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Sensitization Evaluation
Skin Irritation Evaluation
Trial Design
1Treatment groups
Experimental Treatment
Group I: HP-1050 patchExperimental Treatment1 Intervention
HP-1050 and Xulane will be administered simultaneously.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Noven Pharmaceuticals, Inc.Lead Sponsor
8 Previous Clinical Trials
2,339 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger